0001689375
false
0001689375
2023-10-26
2023-10-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 26, 2023
ENTRADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
001-40969 |
81-3983399 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification
No.) |
|
|
|
One Design Center Place
Suite 17-500
|
|
|
Boston, MA |
|
02210 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(857) 520-9158
(Registrant’s telephone number, including
area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading
Symbol |
|
Name of each exchange
on which registered |
Common Stock, par value $0.0001 per share
|
|
TRDA |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive
Agreement.
On October 26, 2023,
Entrada Therapeutics, Inc. (the “Company”) and Vertex Pharmaceuticals Incorporated (“Vertex”) entered into
Amendment No. 1 (the “Amendment to License Agreement”) to the Strategic Collaboration and License Agreement,
dated as of December 7, 2022, by and between the Company and Vertex (the “Original License Agreement” and, as amended
by the Amendment to License Agreement, the “License Agreement”). A copy of the Original License Agreement was filed as
Exhibit 10.16 to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “Commission”)
on March 6, 2023, and is incorporated by reference herein. Concurrently with the execution of the Amendment to License Agreement,
on October 26, 2023, the Company entered into an Amendment No. 1 (the “Amendment to Sublicense Agreement”) to that
certain Sublicense Agreement, dated as of December 7, 2022, by and between the Company and Vertex (the “Original Sublicense
Agreement” and, as amended by the Amendment to Sublicense Agreement, the “Sublicense Agreement”). A copy of the Original
Sublicense Agreement was filed as Exhibit 10.17 to the Company’s Annual Report on Form 10-K, filed with the Commission
on March 6, 2023, and is incorporated by reference herein.
In connection with the
entry into and under the terms of the License Agreement, the Company received an upfront payment of $223.7 million and is eligible to
receive up to $485.0 million upon the achievement of certain research, development, regulatory and commercial milestones. The Amendment
to License Agreement and the Amendment to Sublicense Agreement each clarify a milestone and related payment terms. The terms of the Sublicense
Agreement mirror the terms of the License Agreement.
The Amendment to
License Agreement and Amendment to Sublicense Agreement (collectively, the “Amendments 1”) include certain other
customary terms and conditions. Except as specifically modified or amended by the Amendments, the Original License Agreement and the
Original Sublicense Agreement remain unchanged and in full force and effect. The foregoing is only a brief description of certain
terms of the Amendments, do not purport to be a complete description of the rights and obligations of the parties thereunder, and
are qualified in their entirety by reference to the Amendment to License Agreement and Amendment to Sublicense Agreement, copies of
which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are
incorporated herein by reference.
Item 8.01 Other Events.
In October 2023, the Company achieved a milestone pursuant to
the License Agreement related to preclinical IND-enabling GLP toxicology studies of ENTR-701 that triggered a $17.5 million milestone
payment, which the Company expects to receive in the fourth quarter of 2023.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
104 | Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
† Portions of this exhibit
(indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Entrada Therapeutics, Inc. |
|
|
Date: November 1, 2023 |
/s/ Dipal Doshi |
|
Dipal Doshi |
|
President and Chief Executive Officer |
Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION, MARKED BY
[***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE
OR CONFIDENTIAL.
AMENDMENT NO. 1
TO THE
STRATEGIC COLLABORATION AND LICENSE AGREEMENT
This
AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as
of October 26, 2023 (the “Amendment Effective Date”) by and between, on the one hand, VERTEX
PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Vertex”),
and, on the other hand, Entrada Therapeutics, Inc.,
a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred
to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the
Strategic Collaboration and License Agreement, entered into as of December 7, 2022, between Vertex and Company (the “Agreement”).
Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
RECITALS
WHEREAS,
Vertex and Company desire to amend Section 1.167 and Section 5.3.1 of the Agreement.
WHEREAS,
the Company has [***] as defined under the original Agreement;
WHEREAS, the Parties have agreed [***] to amend the Agreement [***].
NOW,
THEREFORE, in consideration of the respective covenants and agreements set forth herein, the Parties hereto agree as follows:
ARTICLE 1.
AMENDMENTS
| 1.1. | Amendment Date. This Amendment will be effective as of the Amendment Effective Date. |
| 1.2. | Successful Completion of Ongoing Study Definition. Section 1.167 of the Agreement is
hereby amended by deleting it in its entirety and replacing it with the following text: |
1.167. “Successful
Completion of Ongoing Study” means [***].
| 1.3. | Milestone Payment Section. The Section 5.3.1 of the Agreement is hereby amended (i) by
deleting the table contained in Section 5.3.1 and replacing it with the table set forth below and (ii) adding a final sentence
to Section 5.3.1 after the table as set forth below. |
|
Milestone Event |
Milestone Payment |
1 |
[***] |
[***] |
2 |
[***] |
[***] |
3 |
[***] |
[***] |
4 |
[***] |
[***] |
5 |
[***] |
[***] |
As
of the Amendment Effective Date under the Agreement, as amended, the Parties agree and acknowledge [***]
in accordance with Section 5.3.3 promptly after the Amendment Effective Date.
ARTICLE 2.
MISCELLANEOUS
| 2.1. | Effect of Amendment. The amendments set forth in this Amendment shall be deemed to be incorporated
in, and made a part of, the Agreement, and the Agreement and this Amendment shall be read, taken and construed as one and the same agreement
(including with respect to the provisions set forth in Article 11 (Miscellaneous) of the Agreement which shall, as applicable, be
deemed to apply to this Amendment mutatis mutandis). This Amendment shall not be deemed to be an amendment to any other terms and
conditions of the Agreement. Except as expressly amended by this Amendment, the Agreement remains unchanged and in full force and effect. |
| 2.2. | Counterparts. This Amendment may be executed in one or more counterparts, each of which
will be an original and all of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission
(e.g., .pdf), each of which will be binding when received by the applicable Party. The Parties may execute this Agreement by electronically
transmitted signature and such electronically transmitted signature will be as effective as an original executed signature page. |
[SIGNATURE PAGE FOLLOWS]
* - * - * - *
IN
WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their representatives thereunto duly authorized as
of the Amendment Effective Date.
VERTEX
PHARMACEUTICALS INCORPORATED |
|
ENTRADA
THERAPEUTICS, INC. |
|
|
|
By: |
/s/
Charles Wagner |
|
By: |
/s/
Dipal Doshi |
Name: |
Charles Wagner |
|
Name: |
Dipal Doshi |
Title: |
CFO |
|
Title: |
CEO |
Exhibit 10.2
CERTAIN CONFIDENTIAL INFORMATION, MARKED BY
[***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE
OR CONFIDENTIAL.
AMENDMENT NO. 1
TO THE
SUBLICENSE AGREEMENT
This AMENDMENT NO. 1 TO THE
SUBLICENSE AGREEMENT (this “Amendment”) is entered into as of October 26, 2023 (the “Amendment Effective
Date”) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED,
a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Vertex”), and, on the other
hand, Entrada Therapeutics, Inc.,
a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred
to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the
Sublicense Agreement, entered into as of December 7, 2022, between Vertex and Company (the “Agreement”). Capitalized
terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
RECITALS
WHEREAS, Vertex and Company desire to amend
Section 1.117 and Section 6.2.1 of the Agreement.
WHEREAS, the Company has [***] as defined
under the original Agreement;
WHEREAS, the Parties have agreed [***] to amend the Agreement [***].
NOW, THEREFORE, in consideration of the
respective covenants and agreements set forth herein, the Parties hereto agree as follows:
ARTICLE 1.
AMENDMENTS
| 1.1. | Amendment Date. This Amendment will be effective as of the Amendment Effective Date. |
| 1.2. | Successful Completion of Ongoing Study Definition. Section 1.117 of the Agreement is
hereby amended by deleting it in its entirety and replacing it with the following text: |
1.117. “Successful
Completion of Ongoing Study” means [***]
| 1.3. | Milestone Payment Section. Section 6.2.1 of the Agreement is hereby amended (i) by
deleting the table contained in Section 6.2.1 of the Agreement and replacing it with the table set forth below and (ii) adding
a final sentence to Section 6.2.1 of the Agreement after the table as set forth below. |
|
Milestone Event |
Milestone Payment |
1 |
[***] |
[***] |
2 |
[***] |
[***] |
3 |
[***] |
[***] |
4 |
[***] |
[***] |
5 |
[***] |
[***] |
As of the Amendment Effective Date, the
Parties agree and acknowledge [***].
ARTICLE 2.
MISCELLANEOUS
| 2.1. | Effect of Amendment. The amendments set forth in this Amendment shall be deemed to be incorporated
in, and made a part of, the Agreement, and the Agreement and this Amendment shall be read, taken and construed as one and the same agreement
(including with respect to the provisions set forth in Article 12 (Miscellaneous) of the Agreement which shall, as applicable, be
deemed to apply to this Amendment mutatis mutandis). This Amendment shall not be deemed to be an amendment to any other terms and
conditions of the Agreement. Except as expressly amended by this Amendment, the Agreement remains unchanged and in full force and effect. |
| 2.2. | Counterparts. This Amendment may be executed in one or more counterparts, each of which
will be an original and all of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission
(e.g., .pdf), each of which will be binding when received by the applicable Party. The Parties may execute this Agreement by electronically
transmitted signature and such electronically transmitted signature will be as effective as an original executed signature page. |
[SIGNATURE PAGE FOLLOWS]
* - * - * - *
IN WITNESS WHEREOF,
the Parties have caused this Amendment to be executed by their representatives thereunto duly authorized as of the Amendment Effective
Date.
VERTEX
PHARMACEUTICALS INCORPORATED |
|
ENTRADA
THERAPEUTICS, INC. |
|
By: |
/s/
Charles Wagner |
|
By: |
/s/
Dipal Doshi |
Name: |
Charles Wagner |
|
Name: |
Dipal Doshi |
Title: |
CFO |
|
Title: |
CEO |
v3.23.3
Cover
|
Oct. 26, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Oct. 26, 2023
|
Entity File Number |
001-40969
|
Entity Registrant Name |
ENTRADA THERAPEUTICS, INC.
|
Entity Central Index Key |
0001689375
|
Entity Tax Identification Number |
81-3983399
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
One Design Center Place
|
Entity Address, Address Line Two |
Suite 17-500
|
Entity Address, City or Town |
Boston
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02210
|
City Area Code |
857
|
Local Phone Number |
520-9158
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
TRDA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024